Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization

C. Green, A. Y. H. Lim (Stoke on Trent, United Kingdom; Singapore, Singapore)

Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Session: Cystic fibrosis: clinical problems and microbiology in adults
Session type: Thematic Poster Session
Number: 1170
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Green, A. Y. H. Lim (Stoke on Trent, United Kingdom; Singapore, Singapore). Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization. Eur Respir J 2013; 42: Suppl. 57, 1170

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015


Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis
Source: International Congress 2016 – Cystic fibrosis: various aspects
Year: 2016

Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF)
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014


Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 156
Year: 2001


Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Annual Congress 2009 - Update on eosinophilic lung diseases
Year: 2009


Allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2001; 17: 1052-1053
Year: 2001


Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis
Source: Eur Respir J, 56 (2) 2000175; 10.1183/13993003.00175-2020
Year: 2020



Risk factors for allergic bronchopulmonary aspergillosis in paediatric patients with cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010

Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis
Source: Eur Respir J 2003 Oct 01;22(4):592-595
Year: 2003



Vitamin D serum level and pulmonary exacerbations in children with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009


Vitamin D deficiency in asthma patients with allergic bronchopulmonary aspergillosis (ABPA)
Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Year: 2013


Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010


Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis
Source: Eur Respir Rev 2010 19: 349-351
Year: 2010


Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2008; 31: 36-42
Year: 2008



Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015

A new risk factor predicts ABPA in patients with cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015

Real-life experience of Omalizumab in adult Cystic Fibrosis patients with allergic severe asthma and Allergic Bronchopulmonary Aspergillosis
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018

Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis
Source: Eur Respir J 2016; 47: 177-185
Year: 2016